ClinicalTrials.gg

Program

letermovir

Also written as “Letermovir”, “Letermovir tablet” and “Letermovir oral granules”.

Its studies are mostly in Cytomegalovirus Infections, led by 2 companies.

Furthest: phase 3, since May 12, 20148 company-led studies, 1 open or runningNext primary completion: Apr 14, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck71 open or runningphase 3since May 12, 2014May 12, 2014Apr 14, 2028phase 1 · NCT07199465
AiCuris Anti-infective Cures10 open or runningphase 2since Feb 4, 2010Feb 4, 2010none ahead

Also a collaborator on its studies: quintiles-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 4, 2010First study: phase 2 study in HCMV Reactivation or HCMV End-Organ DiseaseNew to AiCuris Anti-infective CuresAiCuris Anti-infective Cures · NCT01063829 · 133 enrolled · United States, Germany
  2. May 12, 2014Merck's first study: phase 3 study in DiseaseNew to MerckMerck · NCT02137772 · 570 enrolled
  3. Feb 19, 2018Phase 3 study in CMV DiseaseMerck · NCT03443869 · 601 enrolled · United States, Argentina, Australia and more
  4. Apr 26, 2019Phase 3 study in Cytomegalovirus InfectionsMerck · NCT03930615 · 220 enrolled · United States, France, Germany and more
  5. May 6, 2019Phase 2 study in Cytomegalovirus InfectionsMerck · NCT03940586 · 65 enrolled · United States, Australia, Colombia and more
  6. Oct 15, 2019Phase 3 study in Cytomegalovirus InfectionsMerck · NCT04129398 · 22 enrolled · Japan
  7. Feb 28, 2023Phase 3 study in Cytomegalovirus InfectionsMerck · NCT05763823 · 120 enrolled · China
  8. Sep 22, 2025Phase 1 study in Cytomegalovirus ProphylaxisMerck · NCT07199465 · 40 planned · United States

Ahead

  1. Apr 14, 2028Primary completion: phase 1 study in Cytomegalovirus ProphylaxisMerck · NCT07199465

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“DNA terminase inhibitor”ChEMBL 37, by rule

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07199465Cytomegalovirus Prophylaxis · United States1RecruitingMerckApr 14, 202840
NCT05763823Cytomegalovirus Infections · China3CompletedMerckApr 18, 2024120
NCT04129398Cytomegalovirus Infections · Japan3CompletedMerckOct 6, 202222
NCT03940586Cytomegalovirus Infections · United States, Australia, Colombia and more2CompletedMerckJan 4, 202365
NCT03930615Cytomegalovirus Infections · United States, France, Germany and more3CompletedMerckOct 27, 2021220
NCT03443869CMV Disease · United States, Argentina, Australia and more3CompletedMerckApr 5, 2022601
NCT02137772Disease3CompletedMerckAug 8, 2016570
NCT01063829HCMV Reactivation or HCMV End-Organ Disease · United States, Germany2CompletedAiCuris Anti-infective CuresOct 2011133

How it is read

Names in the registry

  • “Letermovir”, 5 entries
  • “Letermovir tablet”, 2 entries
  • “Letermovir oral granules”, 1 entry
  • “Letermovir intravenous”, 1 entry
  • “Letermovir IV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.